Results 171 to 180 of about 4,884,808 (294)

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Apoptosis inhibitor of macrophage (AIM/CD5L) as a potential immunomodulator in feline injection-site sarcoma: a hypothesis on tumor-macrophage interactions. [PDF]

Vet Q
Gilbert J, Balka G, Mándoki M, Szilasi A.   +3 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Slug-positive circulating tumor cells in mesenchymal malignancies: what remains to validate. [PDF]

J Cancer Res Clin Oncol
Gholami AA, Mirzaeva D, Soleyeva S.
europepmc   +1 more source

Primary BPH Stromal Cell Cultures Exhibit Heightened Androgen‐Responsiveness

The Prostate, EarlyView.
ABSTRACT Background Benign prostatic hyperplasia (BPH) is the most common disease in aging males. BPH growth is androgen‐dependent, and it appears that androgens preferentially stimulate the growth of BPH as compared to normal prostate. The mechanism of preferential androgen stimulation of BPH growth is not clear.
Wei Chen, Fulu Dong, Mohammad Reza Askarpour, Laura E. Pascal, Rajiv Dhir, Uma Chandran, Bruce L. Jacobs, Donald B. DeFranco, Naoki Yoshimura, Zhou Wang   +9 more
wiley   +1 more source

Equine Sarcoid: From BPV-Driven Oncogenesis to Host-Sustained Tumor Persistence. [PDF]

Pathogens
Dell'Anno F, Trebino C, Fruscione F, De Ciucis CG, De Paolis L, Cappelli K, Razzuoli E.   +6 more
europepmc   +1 more source

Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia

Phytotherapy Research, EarlyView.
Overview of the antileukemic effects of Piper nigrum extract in AML. P. nigrum reduced leukemic cell proliferation and glycolytic metabolism through modulation of the PI3K/AKT/mTOR pathway. In vivo, treatment reduced leukemic burden, improved hematological parameters, prolonged survival, and modulated antitumor immune responses.
Natalia Murillo, Paola Lasso, Claudia Urueña, Susana Fiorentino   +3 more
wiley   +1 more source

γδ T cells and cancer. [PDF]

J Clin Invest
Bolini L, Coffelt SB, Silva-Santos B, Wiest DL, Galluzzi L.   +4 more
europepmc   +1 more source

Phytochemicals as Multitarget Therapeutics in Pancreatic Cancer: Mechanisms, Clinical Evidence, and Translational Challenges

Phytotherapy Research, EarlyView.
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, is aggressive and often diagnosed late, making treatment challenging. This review highlights the potential of phytochemicals, such as curcumin and quercetin, as multitarget agents that influence key carcinogenic pathways. These compounds exhibit anticancer effects by inhibiting processes
Md. Rezaul Islam, Abdur Rauf, F. M. Shourav, Hanan A. Ogaly, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Kamala Badalova, Marcello Iriti   +7 more
wiley   +1 more source

A Six-year Response to Belinostat in a Highly Probable Case of Relapsed/Refractory MF/SS Initially Classified as PTCL-NOS: A Case Report. [PDF]

Onco Targets Ther
Gauthier N, Reimbold P, Bravetti C, Sepporta MV, Le Garff-Tavernier M, Choquet S, Maloum K.   +6 more
europepmc   +1 more source